AURORA, Ontario, April 24 /PRNewswire/ -- Helix BioPharma Corp. (TSX, FSE: "HBP") today announced that John Docherty, president and chief operating officer, will present at the BioFinance 2009 Investor Conference at 3:00 p.m. EDT on Wednesday, April 29, at The Toronto Marriott in Toronto. Mr. Docherty will provide an overview of the company's leading technology platforms, DOS47 and Biphasix(TM), and its current product development programs, L-DOS47 and Topical Interferon Alpha-2b. The slide show portion of the presentation will be posted on the Company's website, www.helixbiopharma.com, on April 29, 2009.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP".
For further information contact: Investor & Media Relations Ian Stone Robert Flamm, Ph.D. Russo Partners LLC Russo Partners LLC Tel: (619) 814-3510 Tel: (212) 845-4226 Fax: (619) 955-5318 Email: Email: email@example.com firstname.lastname@example.org www.russopartnersllc.com
This News Release contains certain forward-looking statements regarding the Company's planned presentation at the BioFinance 2009 Investor Conference and the Company's research and development initiatives, which statements can be identified
|SOURCE Helix BioPharma Corp.|
Copyright©2009 PR Newswire.
All rights reserved